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Background: Colonisation of cystic fibrosis (CF) lungs with Pseudomonas aeruginosa is facilitated by two lectins, 
which bind to the sugar coat of the surface lining epithelia and stop the cilia beating. 
Objectives: We hypothesized that P. aeruginosa lung infection should be cleared by inhalation of fucose and ga-
lactose, which compete for the sugar binding site of the two lectins and thus inhibit the binding of P. aeruginosa. 
Methods: 11 adult CF patients with chronic infection with P. aeruginosa were treated twice daily with inhalation of 
a fucose/galactose solution for 21 days (4 patients only received inhalation, 7 patients received inhalation and 
intravenous antibiotics). Microbial counts of P. aeruginosa, lung function measurements, and inflammatory 
markers were determined before and after treatment. 
Results: The sugar inhalation was well tolerated and no adverse side effects were observed. Inhalation alone as 
well as combined therapy (inhalation and antibiotics) significantly decreased P. aeruginosa in sputum (P < 0.05). 
Both therapies also significantly reduced TNFα expression in sputum and peripheral blood cells (P < 0.05). No 
change in lung function measurements was observed. 
Conclusions: Inhalation of simple sugars is a safe and effective measure to reduce the P. aeruginosa counts in CF 
patients. This may provide an alternative therapeutical approach to treat infection with P. aeruginosa. 
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INTRODUCTION 
Chronic infection of the airways with P. aerugi-
nosa is the leading cause of morbidity and mortality in 
the majority of CF patients (1). This pathogen colonises 
the airways and lungs often in the late teens or early 
twenties and can be controlled for a prolonged time by 
antibiotic treatment (2). However, during the long pe-
riod of infection, it gets resistant towards chemother-
apy and thus the infection cannot be controlled any 
longer. This situation will become more evident in the 
future as the pipeline for the development of antibac-
terial agents runs dry with only five new drugs likely 
to being approved within the next few years (3). 
However, novel strategies to fight the infection 
may be developed by interfering with the bacterial 
attachment to the airway epithelium. P. aeruginosa 
produces two lectins, carbohydrate binding proteins, 
designated P. aeruginosa lectin I (PA-I or Lec A) and II 
(PA-II or Lec B). The first one is specific for galactose, 
the second for fucose (4). Both lectins are used in two 
clever ways to facilitate its pathogenicity. First of all, 
the lectins attach to the covering epithelia by binding 
to the glycocalix of the mammalian cells. By adding 
simple sugars, this attachment can be blocked as 
shown in external otitis caused by P. aeruginosa (5). 
However, simple adhesion via lectin sugar interactions 
would not be enough to persist in the airways as the 
mucociliary elevator would remove all pathogens re-
siding within mucus layer of the airways´ lining fluid. 
As this elevator is driven by the beating of the cilia, 
their inactivation would also facilitate the infection, 
which is indeed the case as these two lectins also im-
mobilise the cilia, thus making the mucociliary eleva-
tor ineffective (6). A case report demonstrated, that 
inhalation of galactose and fucose could indeed re-
move P. aeruginosa from the airways of a non CF pa-Int. J. Med. Sci. 2008, 5 
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tient even if conventional antibiotic treatment failed 
(7). 
The aim of the present study was to investigate 
the effect of this galactose/fucose solution in CF pa-
tients with chronic infection with P. aeruginosa as at 
least the PA-II acts on cilia of CF patients in vitro in the 
same way as in normal controls (8). 
 
SUBJECTS AND METHODS 
Study design 
This study was an open clinical trial. Adult CF 
patients were recruited from the CF outpatient clinic 
and the pulmonary ward of the Department of Medi-
cine I, University Hospital Hamburg-Eppendorf. Pa-
tients had chronic infection with P. aeruginosa (proven 
by positive sputum cultures for at least three years) 
and acute exacerbation at time of recruitment. They 
were randomized to be treated with inhalation of a 10 
ml of 0.1 M fucose / 0.1 M galactose solution in 0.9 % 
NaCl twice daily for 21 days either in the presence or 
absence of therapy with intravenous antibiotics 
(cephalosporine + aminogylcoside). The concentration 
of fucose and galacose was based on data from a pre-
vious study (6). Previous medication including inhaled 
antibiotics, vitamines, pancreatic enzymes, dornase 
alpha, bronchodilatators was continued. Sputum cul-
tures, sputum cell counts, peripheral blood cell counts, 
lung function measurements (vital capacity, VC, 
forced expiratory volume in one second, FEV1), arte-
rial oxygen pressure, inflammatory markers (C reac-
tive protein, IgG, IgE), liver function tests (GOT, GPT) 
and cytokine measurements (tumor necrosis factor-α, 
interleukin-10) were performed before and after 
treatment. The study protocol was approved by the 
local Ethics Committee of the City of Hamburg, Ger-
many. 
Sputum sampling 
After rinsing their mouth with sterile water pa-
tients coughed sputum into a sterile container. One 
part was immediately transported to the Department 
of Microbiology for bacterial culture. The other part 
was weighed, lyophylized with DTT and filtered 
through a nylon mesh. After centrifugation the cell 
pellet was redissolved into phosphate buffered saline 
(PBS) containing 2% fetal calf serum (FCS; Seromed, 
Berlin, Germany). Cell numbers were counted and 
cytospins were prepared for differential cell counts. 
Peripheral blood mononuclear cells (PBMC) and 
serum samples 
PBMC were isolated by centrifugation over Fi-
coll-Paque (Pharmacia, Uppsala, Sweden) and washed 
twice with PBS containing 2% FCS. PMBC were 
counted, cytospins were prepared and differential cell 
counts were preformed. Serum protein levels of tumor 
necrosis factor-α (TNFα) were determined using an 
enzyme linked immunosorbent assay (ELISA, R&D 
Systems, Minneapolis, Minn, USA). C reactive protein 
(CRP), IgG, IgE, GOT, and GPT were measured using 
routine laboratory protocols. 
RNA preparation and RT-PCR 
Sputum cell and PBMC samples, each containing 
RNAzol (Wak, Bad Soden, Germany) and 80,000 cells, 
were stored at -20ºC until further preparation. RNA 
was extracted by treatment with chlorofrome and pre-
cipitated with isopropanol. RNA was re-
verse-transcribed using 2 μl 25 mM MgCl2, 1 μl 
10xPCR buffer, 1 μl 10 mM of each desoxynucleotide 
triphosphate (dNTP), 0.5 μl 50 μM OligodT, 0.5 μl 20 
U/  μl RNAse inhibitor and 0.5 μl 50 U/ μl reverse 
transcriptase (Perkin Elmer Biosystemsm Roche, 
Branchburg, USA). The mixture was incubated at 42ºC 
for 30 min and at 99ºC for 5 min. Samples were stored 
at -20ºC until amplification. 
  The resultant cDNA was amplified by PCR in a 
thermal cycler (Hybaid, Teddington, United Kingdom) 
with a final volume of 100 μl containing 10 μl cDNA 
(IL-18, IL-10) or 5 μl cDNA (β-actin), 10 μl or 15 μl di-
lution buffer, 8 μl 12 mM MgCl2, 8 μl 10xPCR buffer, 
55.5 μl DEPC-H2O, 0.5 μl U/ μl recombinant Taq DNA 
polymerase (Perkin Elmer Biosystems, Roche, 
Branchburg, USA) and 2.0 μl 15 mmol of each primer. 
β-actin served as control. The oligonucleotide primers 
for PCR were based on published mRNA sequences. 
The human β-actin primers were 5’-GTG GGG CGC 
CCC AGG CAC CA-3’ for the upstream primer and 
5’-CTC CTT AAT GTC ACG CAC GAT TTC-3’ for the 
downstream primer. TNFα utilized 5’-CAG AGG GAA 
GAG TTC CCC AG-3’ for the upstream primer and 
5’-CCT TGG TCT GGT AGG AGA CG-3’ for the 
downstream primer. PCR amplification for β-actin was 
performed for 36 cycles (1 min at 94ºC, 1 min at 60ºC, 
40 sec at 72ºC) and for TNFα for 40 cycles (1 min  at 
94°C, 1 min at 60°C, 40 seconds at 72°C). 
Identification of PCR products 
PCR products were analyzed by electrophoresis 
on a 2% agarose gel containing ethidium bromide and 
visualized with UV light. The sizes of the PCR prod-
ucts were compared with the expected PCR product 
length using a molecular weight marker (Boehringer, 
Mannheim, Germany) ran in parallel. 
Densitometric and semiquantitative PCR analysis 
Densitometric analysis was performed with the 
Eagle Eye II Still Video Systeme (Stratagene, La Jolla, Int. J. Med. Sci. 2008, 5 
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USA). The expression was standardized to that of 
β-actin expression from the same reverse-transcribed 
TNFα o r  I L - 1 0  m R N A  s a m p l e .  R a t i o s  o f  c y t o -
kine:β-actin were calculated for semiquantitative RNA 
expression measurement as previously described (9). 
Statistics 
An overall ANOVA, followed by multiple testing 
with the Bonferroni correction, was performed. Dif-
ferences between conditions were assessed by means 
of post hoc pairwise comparison with the Dunnet test. 
A P value of less than 0.05 was considered statistically 
significant. All values are given as means ± SEM if not 
otherwise stated. 
 
 
RESULTS 
Patient characteristics 
A total number of 11 patients (8 male, 3 female, 
median age 27 years) were included. 4 patients were 
treated with inhalation only, 7 patients received inha-
lation and antibiotics. Table 1 summarizes the demo-
graphics of both groups.  
 
 
TABLE 1: Patient group characteristics 
  p. i.   p. i. + i. v. 
N 4  7 
Male/female  2 / 2  3 / 4 
Age (years)  35.2±5.0  31.3±3.5 
P. i.: Inhalation alone. P. i. +i.v: Inhalation + i. v. antibiotics. Mean ± 
SEM 
 
 
 
Fucose/galactose inhalation reduces P. aeruginosa 
in sputum 
Inhalation with fucose/galactose solution alone 
significantly decreased P. aeruginosa in sputum 
(1.032.500 ± 561.714 bacteria/ml pre vs 527.525 ± 
302.347 bacteria/ml post) (P < 0.05). Combination of 
inhalation and intravenous antibiotics also signifi-
cantly reduced bacterial load in sputum (1.007.000 ± 
254.215 bacteria/ml pre vs 500.366 ± 223.592 bacte-
ria/ml post) (P < 0.05). The reduction of P aeruginosa in 
sputum by inhalation alone compared to combined 
therapy was similar. There was no significant differ-
ence between both treatment regimens (P > 0.05) (Fig-
ure 1). 
 
 
Figure 1: Sputum counts of P. aeruginosa before (pre) and after 
(post) treatment with inhalation alone (p. i.) or combined 
treatment with inhalation and i. v. antibiotics (p. i. + i. v.). 
Mean+SEM. *: P < 0.05 vs pre. 
 
Fucose/galactose inhalation decreases sputum neu-
trophils 
The number of inflammatory cells in sputum was 
not significantly altered by either inhalation alone (P > 
0.05) or combined therapy (p = 0.06). However, inha-
lation alone significantly decreased the percentage of 
sputum neutrophils (95.5 ± 1.5% pre vs 84.0 ± 2.0% 
post) (P < 0.05) and significantly increased the per-
centage of sputum macrophages (3.0 ± 0.0% pre vs 11.0 
± 1.0% post) and sputum lymphocytes (0.5 ± 0.5% pre 
vs 2.5 ± 0.5% post) (P < 0.05) (Table 2). In contrast no 
significant changes were observed with combined 
therapy (P > 0.05). In peripheral blood inhalation alone 
and combined therapy did not significantly alter the 
numbers or precentages of PBMC (P > 0.05). 
TABLE 2: Inflammatory cells in sputum 
   p.i.    p.i.+  i.v. 
Pre 3.0±0.0 7.2±3.2  Macrophages (%) 
Post 11.0±1.0* 3.5±1.2 
Pre 0.5±0.5 2.3±0.9  Lymphocytes (%) 
Post 2.5±0.5* 2.3±1.3 
Pre 95.1±1.5 90.2±3.8  Neutrophils (%) 
Post 84.0±2.0* 93.8±1.8 
Pre 1.0±1.0 0.3±0.2  Eosinophils (%) 
Post 2.5±2.5 0.8±0.5 
P. i.: Inhalation alone. P. i. +i.v: Inhalation + i. v. antibiotics. Pre: 
before treatment. Post: after treatment. Mean ± SEM. *: P < 0.05 vs 
pre. 
Fucose/galacatose inhalation does not compromise 
pulmonary function 
There were no significant changes in pO2, VC or 
FEV1 with inhalation alone or combined therapy (P > 
0.05; data not shown). Int. J. Med. Sci. 2008, 5 
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Fucose/galactose inhalation decreases TNFα ex-
pression 
Both inhalation alone and combined therapy sig-
nificantly decreased TNFα mRNA expression in spu-
tum cells (1.31 ± 0.53 pre vs 0.54 ± 0.0 post and 0.94 ± 
0.39 pre vs 0.31 ± 0.13 post) (P < 0.05) (Figure 2 A) and 
in PBMC (0.45 ± 0.29 pre vs 0.24 ± 0.04 post and 0.29 ± 
0.17 pre vs 0.02 ± 0.20 post) (P < 0.05) (Figure 2 B). Ex-
pression of IL-10 mRNA was not significantly changed 
by treatment (P > 0.05; data not shown). TNFα serum 
protein levels were significantly decreased after 
treatment with fucose/galactose inhalation alone (P < 
0.05) but not with combined therapy (P> 0.05) (Figure 
3). 
 
 
 
 
 
 
 
 
 
 
Figure 2: TNFα mRNA expression in sputum cells (A) and in 
PBMC (B) before (pre) and after (post) treatment with inhala-
tion alone (p. i.) or combination of inhalation with antibiotics (p. 
i. + i. v.). Mean+SEM. *: P < 0.05 vs pre. 
 
 
Figure 3: TNFα serum protein levels before (pre) and after 
(post) treatment with inhalation alone (p. i.) or combined 
treatment with inhalation and i. v. antibiotics (p. i. + i. v.). 
Mean+SEM. *: P < 0.05 vs pre. 
Fucose/galactose inhalation does not affect in-
flammatory markers and liver function 
No significant changes of CRP levels, leukocyte 
counts, IgG levels, IgE levels, GOT levels, and GPT 
levels were observed after inhalation alone or com-
bined therapy (P > 0.05, data not shown). 
DISCUSSION 
In the present study we found that inhalation 
with fucose/galactose could reduce P. aeruginosa and 
neutrophils in sputum as well as TNFα expression in 
sputum and peripheral blood of CF patients with acute 
exacerbation. Combination with intravenous antibiot-
ics had no additional effect.  
In our study we used fucose/galactose solution to 
block P. aeruginosa lectins PA-I and PA-II as an alter-
native approach to reduce airway colonisation with 
this bacteria. P. aeruginosa lectins PA-I and PA-II that 
bind to fucose and galactose contribute to the vilru-
lence of this bacterium (10). Therefore blocking of 
these lectins may prevent ongoing colonization and 
inflammation. Although fucose/galactose has been 
demonstrated to be effective in vitro and in vivo (6-8) 
at present there is no information available on the 
clinical effect of fucose/galacatose when given to CF 
patients. 
In the present study both inhalation of 
fucose/galactose solution alone and combined therapy 
of inhalation and antibiotics decreased P. aeruginosa 
load in sputum. Previous studies used hypertonic sa-
line solution or mannitol as inhalation treatment in CF 
(11-14). Inhalation with hypertonic saline solution re-
sulted in improved lung function and reduced exac-
erbation rate (12, 13). There was also a trend towards 
decline of P. aeruginosa in sputum (12, 13). Inhalation 
with mannitol improved cough clearance in CF pa-
tients but its long-term effectiveness has not been de-Int. J. Med. Sci. 2008, 5 
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termined yet (14). In the present study we cannot rule 
out the possibility that part of the effect may be due to 
hypertonicity. However, this does not preclude that 
fucose/galactose solution blocks P. aeruginosa lectins 
and that this is the most important effect. Of course an 
experimental control that inhaled another sugar that is 
not a strong binder to PA lectins would have been 
useful to further support the notion that the effect of 
fucose/galactose is due to restoration of the mucocil-
liary elevator and not due to hypertonicity. We did not 
include another control group because it has been 
clearly shown in previous experiments that fucose and 
galactose can prevent binding of PA lectins I and II (8, 
15). In those studies inhibition of ciliary beats due to 
PA lectins was quantified as well as restoration by 
adding fucose and/or galactose (8, 15).  
Inhalation alone but not combined therapy ame-
liorated inflammatory cell patterns in sputum (less 
neutrophils). This data are surprising. It seems that 
inhalation alone can clear bacteria from the airways 
without a strong inflammatory response due to 
physical elimination of P. aeruginosa via the muco-
ciliary elevator. On the other hand it has to be taken 
into account that interaction of P. aeroginosa with an-
tibotics is complex as “subinhibitory” concentrations 
of antibiotics leads to the suppression of lectin synthe-
sis via the quorum sensing system (16). Antibiotics 
may therefore reduce the effectiveness of 
fucose/galactose. This remains to be further evaluated. 
On the other hand both treatment options significantly 
reduced TNFα mRNA expression in sputum cells and 
PBMC. This finding agrees with the hypothesis that 
antibiotic as well as inhalation therapy has an 
anti-inflammatory effect. Interestingly we only ob-
served a significant reduction of TNFα serum protein 
levels with inhalation alone but not with combination 
therapy. It is tempting to speculate that 
fucose/galacatose inhalation may be able to clear bac-
teria from the lungs without inducing inflammation. 
However, this has to be further evaluated. 
There was no significant increase in lung function 
measurements after inhalation or combined therapy. 
This is mostly due to the small number of patients and 
short period of time studied. 
As the fucose/galactose inhalation is a novel 
treatment, an important question concerns the obser-
vation of adverse effects of this treatment. In the pre-
sent study fucose/galactose inhalation was well toler-
ated and had no adverse effect on liver function. 
However, this does not rule out the possibility that 
over a prolonged period of treatement adverse effects 
may occur. Interestingly, most patients reported a re-
lief from symptoms after inhalation. This may be due 
to lowering the viscosity of mucus. 
As already mentioned inhalation with 
fucose/galactose to reduce P. aeruginosa in CF patients 
is a novel therapeutic approach that has never been 
performed previously. However, the main weakness 
of the present study is the small numbers of patients 
studied and the comparison of inhalation versus in-
halation + antibiotics. Moreover, patients with exac-
erbation but not patients with stable disease were in-
vestigated. Inhalation with fucose/galactose has never 
been used before in a clinical trial with CF patients. For 
methodical considerations we chose patients with 
chronic infection with P. aeruginosa who had an exac-
erbation because these patients are likely to have high 
numbers of P. aeruginosa in sputum. This makes it 
easier to observe an effect in reducing bacterial load. 
For ethical issues we divided the study arms in a ratio 
of 1:2 (inhalation: inhalation + antibiotics). This en-
sured that most of the patients were treated with anti-
biotics and that an effect of inhalation alone and inha-
lation with antibiotics could be evaluated. 
Of course the adequate control would have been 
inhalation with the diluting solution for fucose and 
galactose. However, this study was planned as a pilot 
study to see whether fucose/galactose would have any 
effect. Further studies are warranted to compare 
fucose/galacatose to other inhalations (eg hypertonic 
saline).  
In conclusion the findings in this report show that 
inhalation with fucose/galactose solution could re-
duce P. aeruginosa in sputum of adult CF patients with 
chronic infection with this bacterium. It was well tol-
erated and no serious side effects were observed. Local 
inflammation in the lungs may be attenuated by re-
moval of P. aeruginosa. Future studies will have to 
compare the effect of inhalation with fucose/galactose 
solution with other inhalation regimens. It will also be 
necessary to define which patients are likely to profit 
the most and whether it should be used in regular in-
tervals or not.  
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